Symark

Symark Therapeutics is a preclinical-stage biotechnology company focused on developing first-in-class small molecule inhibitors targeting solute carrier (SLC) transporters. The company's primary focus is on metabolic reprogramming in cancer and inflammatory diseases, specifically by inhibiting MCT1 and MCT4 to disrupt lactate transport in the tumor microenvironment. By targeting these metabolic vulnerabilities, Symark aims to overcome drug resistance and enhance the efficacy of existing therapies, including immunotherapies. Their lead program, SY-101, is a dual MCT1/4 inhibitor designed for the treatment of various solid tumors.